-
EP2784084
European procedure
Extract from the Register of European Patents
EP About this file: EP2784084
| EP2784084 - Antagonist antibodies to IL-17A/F heterologous polypeptides [Right-click to bookmark this link] | |||
| Former [2014/40] | IL-17 A/F heterologous polypeptides and therapeutics uses thereof | ||
| [2019/14] | Status | Patent maintained as amended Status updated on 01.09.2023 Database last updated on 02.09.2024 | |
| Former | The patent has been granted Status updated on 21.06.2019 | ||
| Former | Grant of patent is intended Status updated on 17.03.2019 | ||
| Former | Examination is in progress Status updated on 11.11.2016 | Most recent event Tooltip | 01.09.2023 | Patent maintained (B2 publication) | published on 04.10.2023 [2023/40] | Applicant(s) | For all designated states Novartis Pharma AG Lichtstrasse 35 4056 Basel / CH | [2023/40] |
| Former [2020/52] | For all designated states Novartis Pharma AG Lichtstrasse 35 4056 Basel / CH | ||
| Former [2019/30] | For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US | ||
| Former [2014/40] | For all designated states Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990 / US | Inventor(s) | 01 /
Arnott, David 366 E. 40th Avenue San Mateo, CA 94403 / US | 02 /
Gurney, Austin 946 Diamond Street San Francisco, CA 94114 / US | 03 /
Hass, Phillip 558 Sierra Street Moss Beach, CA 94038 / US | 04 /
Lee, James 1 DNA Way South San Francisco, CA 94080-4990 / US | 05 /
Wu, Yan 1160 Blythe Street Foster City, CA 94404 / US | [2014/40] | Representative(s) | Breuer Friedrich Hahner Patentanwälte PartG mbB Brienner Straße 1 80333 München / DE | [2023/40] |
| Former [2019/30] | Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | ||
| Former [2014/40] | Denison, Christopher Marcus Mewburn Ellis LLP 33 Gutter Lane London EC2V 8AS / GB | Application number, filing date | 14163686.0 | 02.06.2004 | [2014/40] | Priority number, date | US20030485599P | 08.07.2003 Original published format: US 485599 P | US20030486457P | 11.07.2003 Original published format: US 486457 P | [2014/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2784084 | Date: | 01.10.2014 | Language: | EN | [2014/40] | Type: | B1 Patent specification | No.: | EP2784084 | Date: | 24.07.2019 | Language: | EN | [2019/30] | Type: | B2 New European patent specification | No.: | EP2784084 | Date: | 04.10.2023 | Language: | EN | [2023/40] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 01.09.2014 | Classification | IPC: | C07K16/24, A61K39/395 | [2019/14] | CPC: |
C07K16/244 (EP,US);
C07K14/54 (EP,KR,US);
A61K38/17 (KR);
A61K38/2073 (US);
A61P1/00 (EP);
A61P1/04 (EP);
A61P1/16 (EP);
A61P11/00 (EP);
A61P11/02 (EP);
A61P11/06 (EP);
A61P13/12 (EP);
A61P17/00 (EP);
A61P17/04 (EP);
A61P17/06 (EP);
A61P19/00 (EP);
A61P19/02 (EP);
A61P21/00 (EP);
A61P25/00 (EP);
A61P25/02 (EP);
A61P27/16 (EP);
A61P29/00 (EP);
A61P3/10 (EP);
A61P31/04 (EP);
A61P31/10 (EP);
A61P31/12 (EP);
A61P31/16 (EP);
A61P31/18 (EP);
A61P31/20 (EP);
A61P31/22 (EP);
A61P33/00 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
A61P5/00 (EP);
A61P7/00 (EP);
A61P7/06 (EP);
A61P9/00 (EP);
C07K16/00 (KR);
C12N15/11 (KR);
G01N33/6869 (EP,US);
A61K2039/505 (US);
A61K38/00 (EP,US);
C07K2317/21 (EP,US);
C07K2317/24 (US);
C07K2317/31 (US);
C07K2317/32 (US);
C07K2317/33 (US);
C07K2317/34 (US);
C07K2317/55 (EP,US);
C07K2317/565 (EP,US);
C07K2317/622 (US);
C07K2317/75 (US);
C07K2317/76 (US);
C07K2317/92 (US);
C07K2319/30 (US);
C07K2319/40 (US);
|
| Former IPC [2014/40] | C07K14/54, C12N15/24, C07K16/24, A61K38/20, A61K39/395, G01N33/53 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2015/19] |
| Former [2014/40] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | Title | German: | Heterologe IL-17A/F-Polypeptide und deren therapeutische Verwendungen | [2023/10] | English: | Antagonist antibodies to IL-17A/F heterologous polypeptides | [2019/14] | French: | Polypeptides hétérologues IL-17 A/F et utilisations thérapeutiques associées | [2023/10] |
| Former [2014/40] | Heterologe IL-17A/F-Polypeptide und deren therapeutische Verwendungen | ||
| Former [2014/40] | IL-17 A/F heterologous polypeptides and therapeutics uses thereof | ||
| Former [2014/40] | Polypeptides hétérologues IL-17 A/F et utilisations thérapeutiques associées | Examination procedure | 31.03.2015 | Examination requested [2015/19] | 21.07.2015 | Amendment by applicant (claims and/or description) | 09.11.2016 | Despatch of a communication from the examining division (Time limit: M06) | 24.08.2017 | Reply to a communication from the examining division | 07.12.2017 | Despatch of a communication from the examining division (Time limit: M06) | 16.07.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 24.09.2018 | Reply to a communication from the examining division | 07.02.2019 | Despatch of a communication from the examining division (Time limit: M02) | 08.02.2019 | Reply to a communication from the examining division | 15.02.2019 | Observations by third parties | 02.03.2019 | Observations by third parties | 18.03.2019 | Communication of intention to grant the patent | 09.05.2019 | Observations by third parties | 07.06.2019 | Fee for grant paid | 07.06.2019 | Fee for publishing/printing paid | 07.06.2019 | Receipt of the translation of the claim(s) | 17.11.2021 | Observations by third parties | Parent application(s) Tooltip | EP04754234.5 / EP1641822 | EP10010285.4 / EP2277908 | Divisional application(s) | EP19175735.0 / EP3594228 | Opposition(s) | Opponent(s) | 01
24.07.2019
10.06.2020
WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | 02
16.03.2020
02.11.2022
WITHDRAWN Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative Ingham, Stephen Howard, et al, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | 03
22.04.2020
06.12.2021
WITHDRAWN Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | 04
23.04.2020
26.07.2021
WITHDRAWN UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE Opponent's representative J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | 05
30.08.2021
02.11.2022
INTERVENTION WITHDRAWN Eli Lilly Gesellschaft m.b.H Erdberger Lände 26A 1030 Wien / AT Opponent's representative Ingham, Stephen Howard, et al, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [2022/49] |
| Former [2022/10] | |||
| Opponent(s) | 01
24.07.2019
10.06.2020
WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
24.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative Ingham, Stephen Howard, et al, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | |||
| 03
22.04.2020
06.12.2021
WITHDRAWN Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | |||
| 04
23.04.2020
26.07.2021
WITHDRAWN UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE Opponent's representative J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | |||
| 05
30.08.2021
02.09.2021
INTERVENTION ADMISSIBLE Eli Lilly Gesellschaft m.b.H Erdberger Lände 26A 1030 Wien / AT Opponent's representative Ingham, Stephen Howard, et al, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | |||
| Former [2022/02] | |||
| Opponent(s) | 01
24.07.2019
10.06.2020
WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
24.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| 03
22.04.2020
06.12.2021
WITHDRAWN Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | |||
| 04
23.04.2020
26.07.2021
WITHDRAWN UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE Opponent's representative J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | |||
| 05
30.08.2021
02.09.2021
INTERVENTION ADMISSIBLE Eli Lilly Gesellschaft m.b.H Erdberger Lände 26A 1030 Wien / AT Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| Former [2021/44] | |||
| Opponent(s) | 01
24.07.2019
10.06.2020
WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
24.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| 03
22.04.2020
24.04.2020
ADMISSIBLE Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | |||
| 04
23.04.2020
26.07.2021
WITHDRAWN UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE Opponent's representative J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | |||
| 05
30.08.2021
02.09.2021
INTERVENTION ADMISSIBLE Eli Lilly Gesellschaft m.b.H Erdberger Lände 26A 1030 Wien / AT Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| Former [2021/40] | |||
| Opponent(s) | 01
24.07.2019
10.06.2020
WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
24.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| 03
22.04.2020
24.04.2020
ADMISSIBLE Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | |||
| 04
23.04.2020
02.06.2020
ADMISSIBLE UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE Opponent's representative J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | |||
| 05
30.08.2021
02.09.2021
INTERVENTION ADMISSIBLE Eli Lilly Gesellschaft m.b.H Erdberger Lände 26A 1030 Wien / AT Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| Former [2021/37] | |||
| Opponent(s) | 01
24.07.2019
10.06.2020
WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
24.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| 03
22.04.2020
24.04.2020
ADMISSIBLE Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | |||
| 04
23.04.2020
02.06.2020
ADMISSIBLE UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE Opponent's representative J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | |||
| Former [2020/29] | |||
| Opponent(s) | 01
24.07.2019
10.06.2020
WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Marshall, Cameron John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
24.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| 03
22.04.2020
24.04.2020
ADMISSIBLE Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | |||
| 04
23.04.2020
02.06.2020
ADMISSIBLE UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE Opponent's representative J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | |||
| Former [2020/23] | |||
| Opponent(s) | 01
24.07.2019
WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Marshall, Cameron John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
24.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| 03
22.04.2020
24.04.2020
ADMISSIBLE Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | |||
| 04
23.04.2020
ADMISSIBLE UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE Opponent's representative J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | |||
| Former [2020/22] | |||
| Opponent(s) | 01
24.07.2019
Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Marshall, Cameron John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
24.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| 03
22.04.2020
ADMISSIBLE Merck Patent GmbH Frankfurter Strasse 250 64293 Darmstadt / DE Opponent's representative Bird & Bird LLP Maximiliansplatz 22 80333 München / DE | |||
| Former [2020/17] | |||
| Opponent(s) | 01
24.07.2019
Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Marshall, Cameron John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
| 02
16.03.2020
ADMISSIBLE Eli Lilly and Company / Lilly Deutschland GmbH Lilly Corporate Center / Werner-Reimers-Straße 2-4 Indianapolis, IN 46285/US /61352 Homburg v.d.H./DE / US Opponent's representative von Renesse, Dorothea, et al, et al König-Szynka-Tilmann-von Renesse Patentanwälte Partnerschaft mbB Mönchenwerther Str. 11 40545 Düsseldorf / DE | |||
| Former [2019/35] | |||
| Opponent(s) | 01
24.07.2019
Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Marshall, Cameron John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | 12.06.2020 | No. 01: Notification indicating deficiencies in the notice of opposition | 12.06.2020 | No. 01: Reply to notification indicating deficiencies in the notice of opposition | 07.07.2020 | Invitation to proprietor to file observations on the notice of opposition | 17.11.2020 | Reply of patent proprietor to notice(s) of opposition | 10.12.2021 | Cancellation of oral proceeding that was planned for 16.02.2022 | 28.01.2022 | Despatch of a communication from the opposition division (Time limit: M01) | 16.02.2022 | Date of oral proceedings | 04.03.2022 | Reply to a communication from the opposition division | 13.02.2023 | Cancellation of oral proceeding that was planned for 07.06.2023 | 16.02.2023 | Despatch of interlocutory decision in opposition | 26.02.2023 | Legal effect of interlocutory decision in opposition | 02.06.2023 | Despatch of communication that the patent will be maintained as amended | 07.06.2023 | Date of oral proceedings | 29.08.2023 | Fee for printing new specification paid | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 24.09.2018 | Request for further processing filed | 24.09.2018 | Full payment received (date of receipt of payment) Request granted | 04.10.2018 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 24.08.2017 | Request for further processing filed | 24.08.2017 | Full payment received (date of receipt of payment) Request granted | 08.09.2017 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 21.07.2015 | Request for further processing filed | 21.07.2015 | Full payment received (date of receipt of payment) Request granted | 30.07.2015 | Decision despatched | Fees paid | Renewal fee | 23.04.2014 | Renewal fee patent year 03 | 23.04.2014 | Renewal fee patent year 04 | 23.04.2014 | Renewal fee patent year 05 | 23.04.2014 | Renewal fee patent year 06 | 23.04.2014 | Renewal fee patent year 07 | 23.04.2014 | Renewal fee patent year 08 | 23.04.2014 | Renewal fee patent year 09 | 23.04.2014 | Renewal fee patent year 10 | 23.04.2014 | Renewal fee patent year 11 | 05.06.2015 | Renewal fee patent year 12 | 31.03.2016 | Renewal fee patent year 13 | 08.06.2017 | Renewal fee patent year 14 | 08.06.2018 | Renewal fee patent year 15 | 10.06.2019 | Renewal fee patent year 16 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | GB | 10.11.2020 | [2022/09] | Documents cited: | Search | [XDI]WO0146420 (GENENTECH INC [US]); | Examination | WO9704097 | JP2000186046 | by applicant | US577300 | US3773919 | US3896111 | US4137230 | US4151042 | EP0003089 | US4179337 | US4248870 | US4256746 | US4260608 | US4265814 | US4275149 | EP0036776 | US4294757 | US4301144 | US4307016 | US4308268 | US4308269 | US4309428 | US4313946 | US4315929 | US4317821 | US4322348 | US4331598 | US4361650 | US4362663 | US4364866 | US4371533 | US4376110 | EP0073657 | US4399216 | US4424219 | US4450254 | EP0117060 | EP0117058 | WO8403506 | WO8403564 | US4485045 | US4496689 | EP0139383 | US4544545 | EP0183070 | US4640835 | US4657760 | US4670417 | US4675187 | US4676980 | WO8705330 | EP0244234 | US4708871 | US4736866 | US4791192 | EP0307247 | US4816567 | DD266710 | US4833092 | WO8905859 | GB2211504 | US4870009 | US4873191 | EP0362179 | US4943529 | US4946783 | WO9010048 | WO9010448 | EP0394538 | WO9013646 | WO9013641 | EP0402226 | EP0404097 | WO9100357 | WO9100360 | WO9104753 | US5010182 | US5013556 | WO9106629 | US5053394 | US5122469 | WO9220373 | US5206344 | US5208020 | WO9308829 | WO9311161 | US5223409 | US5225212 | US5229275 | WO9316185 | WO9321232 | WO9404690 | WO9410308 | WO9411026 | EP0616812 | US5364934 | US5403484 | US5416064 | US5428130 | US5427908 | US5432018 | WO9534683 | US5498538 | US5498530 | WO9607399 | US5500362 | WO9616673 | US5536637 | US5545806 | US5545807 | US5556762 | EP0425235 | US5565332 | US5567610 | US5569825 | US5571689 | US5571894 | US5573905 | US5580717 | WO9640072 | US5587458 | US5591669 | WO9703692 | WO9709446 | US5627024 | WO9717852 | US5641870 | US5654010 | US5663143 | WO9733551 | WO9735196 | WO9738731 | WO9746251 | US5698426 | WO9747314 | WO9802463 | US5712374 | US5714586 | US5723286 | US5723323 | US5731168 | US5734018 | WO9814277 | US5739277 | US5739116 | WO9815833 | US5750373 | WO9820169 | WO9820159 | WO9820036 | US5763192 | US5767285 | US5766905 | US5770701 | US5770710 | US5770434 | US5821337 | US5837234 | US5869046 | US5877296 | WO0000823 | WO0039585 | US2002177188 | Opposition | US6043344 | WO0020593 | JP2000186046 | WO0069463 | WO0146420 | US6274711 | WO02058717 | WO02064739 | US8779101 | GB1641822 | WO9518826 | EP0451216 | WO2005010044 | EP1641822 | US10011654 |